ATE519498T1 - Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen - Google Patents

Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen

Info

Publication number
ATE519498T1
ATE519498T1 AT07703319T AT07703319T ATE519498T1 AT E519498 T1 ATE519498 T1 AT E519498T1 AT 07703319 T AT07703319 T AT 07703319T AT 07703319 T AT07703319 T AT 07703319T AT E519498 T1 ATE519498 T1 AT E519498T1
Authority
AT
Austria
Prior art keywords
somatostatin
combination
receptor subtypes
analogas
different selectivity
Prior art date
Application number
AT07703319T
Other languages
English (en)
Inventor
Herbert Schmid
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE519498T1 publication Critical patent/ATE519498T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
AT07703319T 2006-02-09 2007-02-07 Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen ATE519498T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0602639.7A GB0602639D0 (en) 2006-02-09 2006-02-09 Organic compounds
PCT/EP2007/001036 WO2007096055A1 (en) 2006-02-09 2007-02-07 Combination of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes

Publications (1)

Publication Number Publication Date
ATE519498T1 true ATE519498T1 (de) 2011-08-15

Family

ID=36119810

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07703319T ATE519498T1 (de) 2006-02-09 2007-02-07 Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen

Country Status (15)

Country Link
US (2) US8450272B2 (de)
EP (1) EP1988914B1 (de)
JP (1) JP5189993B2 (de)
KR (1) KR101466410B1 (de)
CN (1) CN101378775B (de)
AT (1) ATE519498T1 (de)
AU (1) AU2007218297B2 (de)
BR (1) BRPI0707560B8 (de)
CA (1) CA2638065C (de)
ES (1) ES2369155T3 (de)
GB (1) GB0602639D0 (de)
PL (1) PL1988914T3 (de)
PT (1) PT1988914E (de)
RU (1) RU2451520C2 (de)
WO (1) WO2007096055A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005325510B2 (en) 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
US9314508B2 (en) 2008-07-08 2016-04-19 Novartis Ag Use of somatostatin analogs in control of hypoglycemia
PE20150195A1 (es) * 2012-05-25 2015-02-27 Camarus Ab Formulaciones de agonistas del receptor de somatostatina
TWI633887B (zh) 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
WO2014165607A2 (en) * 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
DK3007704T3 (da) * 2013-06-13 2021-03-29 Antisense Therapeutics Ltd Kombinationsterapi til akromegali
US20240165282A1 (en) * 2021-03-04 2024-05-23 Starget Pharma Ltd. Conformational constrained somatostatin receptor 3 peptide ligands and their conjugates and uses thereof
CN120131956A (zh) * 2023-12-11 2025-06-13 中山大学中山眼科中心 生长激素抑制剂的用途、和含有生长激素抑制剂的药物组合物、制剂、及其装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2774591B1 (fr) * 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
RU2352578C2 (ru) * 2001-03-06 2009-04-20 Иль Консорцио Феррара Ричерке Способ модуляции пролиферации клеток медуллярной карциномы щитовидной железы
MXPA03012042A (es) 2001-06-25 2006-05-22 Il Consorzio Ferrara Richerche Composiciones farmaceuticas que inhiben la proliferacion de adenomas pituitarios y metodos de uso de las mismas.
WO2003045320A2 (en) * 2001-11-21 2003-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Somatostatin analog and uses thereof
WO2005041901A2 (en) * 2003-11-03 2005-05-12 Elixir Pharmaceuticals, Inc. Therapeutics using somatostatin agonists
CN1914310A (zh) * 2003-12-03 2007-02-14 宝洁公司 清洁浴室表面的方法、制品及组合物
SI1787658T1 (sl) * 2005-11-10 2012-07-31 Chemi Spa Formulacije z trajnim sproščanjem somatostatin analognih inhibitorjev rastnega hormona
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
RU2008136073A (ru) 2010-03-20
US8450272B2 (en) 2013-05-28
PL1988914T3 (pl) 2012-01-31
AU2007218297B2 (en) 2010-09-09
PT1988914E (pt) 2011-10-18
CA2638065A1 (en) 2007-08-30
JP2009526002A (ja) 2009-07-16
GB0602639D0 (en) 2006-03-22
CN101378775B (zh) 2013-06-12
AU2007218297A1 (en) 2007-08-30
US20090029910A1 (en) 2009-01-29
RU2451520C2 (ru) 2012-05-27
BRPI0707560B1 (pt) 2019-06-04
BRPI0707560B8 (pt) 2021-05-25
BRPI0707560A2 (pt) 2011-05-10
CN101378775A (zh) 2009-03-04
US9149510B2 (en) 2015-10-06
ES2369155T3 (es) 2011-11-25
EP1988914A1 (de) 2008-11-12
WO2007096055A1 (en) 2007-08-30
KR101466410B1 (ko) 2014-11-27
KR20080106896A (ko) 2008-12-09
EP1988914B1 (de) 2011-08-10
CA2638065C (en) 2016-03-29
JP5189993B2 (ja) 2013-04-24
US20130237480A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
ATE469895T1 (de) Cgrp-rezeptorantagonisten
PT1988914E (pt) Combinação de análogos de somatostatina com diferente selectividade para subtipos do receptor da somatostatina humana
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
MX384206B (es) Formulaciones de inhibidores de dpp iv
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
CY1110882T1 (el) Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
ATE484505T1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
ECSP067121A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
EA200802104A1 (ru) Применение композиций, содержащих антагонисты каппа-опиоидных рецепторов, для лечения диссоциативных расстройств
SI2201002T1 (sl) Antagonisti 5-ht7 receptorja
MEP1008A (xx) 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
WO2008142319A3 (fr) Analogues peptidiques des recepteurs des melanocortines
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
ATE525370T1 (de) Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1988914

Country of ref document: EP